Compare VTYX & SSII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VTYX | SSII |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.9M | 1.1B |
| IPO Year | 2021 | N/A |
| Metric | VTYX | SSII |
|---|---|---|
| Price | $13.98 | $5.12 |
| Analyst Decision | Hold | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | ★ 5.9M | 70.2K |
| Earning Date | 02-26-2026 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $36,066,457.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 158.36 |
| 52 Week Low | $0.78 | $3.02 |
| 52 Week High | $25.00 | $22.42 |
| Indicator | VTYX | SSII |
|---|---|---|
| Relative Strength Index (RSI) | 75.73 | 41.64 |
| Support Level | $7.08 | $5.25 |
| Resistance Level | $14.07 | $6.01 |
| Average True Range (ATR) | 0.27 | 0.46 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 83.47 | 6.31 |
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The company earns the majority of its revenue from India.